To enhance the tumor-targeting capability of the nanovesicles, we successfully modified the NGR peptide onto the surface of BNVs using EDC/NHS crosslinking, resulting in NGR-ALKBH5-siRNA-BNVs. This evidence concerns the gene ALKBH5 and neoplasm.